{"id":"W3089265467","doi":"10.1016/j.annonc.2020.08.958","title":"819P Efficacy and safety of niraparib in older patients (pts) with advanced ovarian cancer (OC): Results from the PRIMA/ENGOT-OV26/GOG-3012 trial","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"North Carolina GlaxoSmithKline Foundation","keywords":"Medicine; Internal medicine; Adverse effect; Ovarian cancer; Clinical endpoint; Hazard ratio; Progression-free survival; Urology; Randomized controlled trial; Gastroenterology; Oncology; Chemotherapy; Gynecology; Cancer; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008406514,0.000576351,0.001253246,0.0001560124,0.0001828112,0.0006755911,0.0002858252,0.000608885,0.0030193],"category_scores_gemma":[0.001200514,0.000223036,0.001058556,0.0003488212,0.0003938663,0.0006950189,0.0003371503,0.001909778,0.0006956205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004146223,"about_ca_system_score_gemma":0.0003441676,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000330542,"about_ca_topic_score_gemma":0.0009586699,"domain_scores_codex":[0.9997451,0.0001140734,0.00001794571,0.00005460343,0.0000286688,0.00003947916],"domain_scores_gemma":[0.9994878,0.0001312194,0.0001560272,0.00004288861,0.00002530535,0.0001567804],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6953357,0.003373481,0.02988117,0.002473646,0.004250256,0.0004583228,0.0001693104,0.002468052,0.01272777,0.00061521,0.009726883,0.2385201],"study_design_scores_gemma":[0.5803136,0.1491134,0.2222791,0.0005478938,0.006691035,0.00180001,0.0002426721,0.003025513,0.00304327,0.003103518,0.02967329,0.0001666389],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775705,0.01298274,0.0002270205,0.001114181,0.0002208759,0.0002447451,0.002083045,0.00005672189,0.005500174],"genre_scores_gemma":[0.9867266,0.006264859,0.000333846,0.001294739,0.0003028137,0.0001897276,0.002653195,0.00002360522,0.002210707],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0030193,"threshold_uncertainty_score":0.0101006,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0793094299621809,"score_gpt":0.3875644351331859,"score_spread":0.308255005171005,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}